-
公开(公告)号：US20200138760A1
公开(公告)日：2020-05-07
申请号：US16569055
申请日：2019-09-12
IPC分类号： A61K31/198 , A61K45/06 , A61K31/12 , A61K31/353 , A61K31/603 , A61K31/423 , A61K31/192
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
-
公开(公告)号：US10786473B2
公开(公告)日：2020-09-29
申请号：US16569055
申请日：2019-09-12
IPC分类号： A61K31/165 , A61K31/12 , A61K31/198 , A61K45/06 , A61K31/353 , A61K31/603 , A61K31/423 , A61K31/192
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
-
公开(公告)号：US20170304243A1
公开(公告)日：2017-10-26
申请号：US15448054
申请日：2017-03-02
IPC分类号： A61K31/198 , A61K31/603 , A61K31/423 , A61K31/353 , A61K31/192 , A61K45/06 , A61K31/12
CPC分类号： A61K31/198 , A61K31/12 , A61K31/192 , A61K31/353 , A61K31/423 , A61K31/603 , A61K45/06 , A61K2300/00
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
-
公开(公告)号：US11564899B2
公开(公告)日：2023-01-31
申请号：US17005893
申请日：2020-08-28
IPC分类号： A61K31/165 , A61K9/16 , A61K31/198 , A61K45/06 , A61K31/12 , A61K31/353 , A61K31/603 , A61K31/423 , A61K31/192
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
-
公开(公告)号：US20190091188A1
公开(公告)日：2019-03-28
申请号：US16101882
申请日：2018-08-13
IPC分类号： A61K31/198 , A61K31/192 , A61K31/423 , A61K45/06 , A61K31/603 , A61K31/12 , A61K31/353
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
-
公开(公告)号：US09610270B2
公开(公告)日：2017-04-04
申请号：US14353459
申请日：2012-10-23
IPC分类号： A61K31/42 , A61K31/165 , A61K31/12 , A61K31/198 , A61K45/06 , A61K31/353 , A61K31/423 , A61K31/603 , A61K31/192
CPC分类号： A61K31/198 , A61K31/12 , A61K31/192 , A61K31/353 , A61K31/423 , A61K31/603 , A61K45/06 , A61K2300/00
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
-
公开(公告)号：US10449169B2
公开(公告)日：2019-10-22
申请号：US16101882
申请日：2018-08-13
IPC分类号： A61K31/165 , C07D263/58 , C07D263/20 , A61K31/198 , A61K45/06 , A61K31/12 , A61K31/353 , A61K31/423 , A61K31/603 , A61K31/192
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
-
公开(公告)号：US10045956B2
公开(公告)日：2018-08-14
申请号：US15448054
申请日：2017-03-02
IPC分类号： A61K31/42 , A61K31/165 , A61K31/16 , A61K31/198 , A61K45/06 , A61K31/12 , A61K31/353 , A61K31/423 , A61K31/603 , A61K31/192
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
-
公开(公告)号：US20140296188A1
公开(公告)日：2014-10-02
申请号：US14353459
申请日：2012-10-23
IPC分类号： A61K31/423 , A61K31/12 , A61K31/192 , A61K31/353 , A61K31/198
CPC分类号： A61K31/198 , A61K31/12 , A61K31/192 , A61K31/353 , A61K31/423 , A61K31/603 , A61K45/06 , A61K2300/00
摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
摘要翻译： 提供了一种用于预防和/或治疗转甲状腺素相关淀粉样变性的儿茶酚-O-甲基转移酶（COMT）抑制剂。 还提供了一种儿茶酚-O-甲基转移酶（COMT）抑制剂，用于与另一种COMT抑制剂，苯并恶唑衍生物，碘代氟尼柳尼，二氟尼柳，白藜芦醇，牛磺熊去氧胆酸，多西环素联合治疗中预防和/或治疗转甲状腺素蛋白相关淀粉样变性 ，或表没食子儿茶素-3-没食子酸酯。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.015 秒)
